Neelima Gupta

Neelima Gupta

Auto-generated profile, based on publicly available information

Neelima Gupta

Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2019 in Glia
Verified
Journal Article
Open access
PDF file
GSGenevieve Saw
Genevieve Saw
KKKumar Krishna
Kumar Krishna
NGNeelima Gupta
Neelima Gupta
TSTuck Wah Soong
Tuck Wah Soong
KMKarthik Mallilankaraman
Karthik Mallilankaraman
SDS Thameem Dheen
S Thameem Dheen
Microglia are the main form of immune defense in the central nervous system. Microglia express phosphatidylinositol 3‐kinase (PI3K), which has been shown to play a significant role in synaptic plasticity in neurons and inflammation via microglia. This study shows that microglial PI3K is regulated epigenetically through histone modifications and posttranslationally through sumoylation and is involved in long‐term potentiation (LTP) by modulating the expression of brain‐derived neurotrophic factor (BDNF), which has been shown to be involved in neuronal synaptic plasticity. Sodium butyrate, a histone deacetylase inhibitor, upregulates PI3K expression, the phosphorylation of its downstream effectors, AKT and cAMP response element‐binding protein (CREB), and the expression of BDNF in microglia, suggesting that BDNF secretion is regulated in microglia via epigenetic regulation of PI3K. Further, knockdown of SUMO1 in BV2 microglia results in a decrease in the expression of PI3K, the phosphorylation of AKT and CREB, as well as the expression of BDNF. These results suggest that microglial PI3K is epigenetically regulated by histone modifications and posttranslationally modified by sumoylation, leading to altered expression of BDNF. Whole‐cell voltage‐clamp showed the involvement of microglia in neuronal LTP, as selective ablation or disruption of microglia with clodronate in rat hippocampal slices abolished LTP. However, LTP was rescued when the same hippocampal slices were treated with active PI3K or BDNF, indicating that microglial PI3K/AKT signaling contributes to LTP and synaptic plasticity. Understanding the mechanisms by which microglial PI3K influences synapses provides insights into the ways it can modulate synaptic transmission and plasticity in learning and memory.

2 September 2018 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
NGNeelima Gupta
Neelima Gupta
SSSukanya Shyamasundar
Sukanya Shyamasundar
RPRadhika Patnala
Radhika Patnala
AKAparna Karthikeyan
Aparna Karthikeyan
TAThiruma V. Arumugam
Thiruma V. Arumugam
SDS Thameem Dheen
S Thameem Dheen
Introduction: Chronic activation of microglia is the hallmark of numerous neuropathologies such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The activated microglia perpetuate inflammation by releasing an array of pro-inflammatory and neurotoxic factors, which eventually exacerbate neurotoxicity and neurodegeneration upon chronic activation of these cells. However, under acute conditions, activated microglia elicit pro-inflammatory as well as anti-inflammatory responses that are associated with neuroprotection. Given the role of microglia in neuroinflammation, recent studies have attempted to unravel the mechanisms that aid to establish microglial cell-based therapy. Areas covered: While total suppression of microglial activation may compromise its beneficial role in tissue repair in the aftermath of an insult, the benefits of modulating microglial activation and promoting microglia polarization to a neuroprotective phenotype have been highlighted recently. Expert opinion: So far, the therapeutic strategy focussed on neutralizing microglia-mediated neuroinflammation using drugs that block the release of pro-inflammatory mediators has limitations, such as unwarranted side effects. Recent advances reveal several alternative molecular targets and potential epi-drugs that are capable of modulating microglial function and promoting neuroprotection. This review discusses the recent progress made in understanding the mechanisms of microglia-mediated neuroinflammation in various neuropathologies, and the emerging anti-inflammatory therapeutic strategies in this field.

21 May 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
NGNeelima Gupta
Neelima Gupta
SJShweta Jadhav
Shweta Jadhav
KTKai-Leng Tan
Kai-Leng Tan
GSGenevieve Saw
Genevieve Saw
KMKarthik Babu Mallilankaraman
Karthik Babu Mallilankaraman
SDS Thameem Dheen
S Thameem Dheen
Microglia, the innate immune effector cells of the mammalian central nervous system (CNS), are involved in the development, homeostasis, and pathology of CNS. Microglia become activated in response to various insults and injuries and protect the CNS by phagocytosing the invading pathogens, dead neurons, and other cellular debris. Recent studies have demonstrated that the epigenetic mechanisms ensure the coordinated regulation of genes involved in microglial activation. In this study, we performed a microRNA (miRNA) microarray in activated primary microglia derived from rat pup’s brain and identified differentially expressed miRNAs targeting key genes involved in cell survival, apoptosis, and inflammatory responses. Interestingly, miR-142-3p, one of the highly up-regulated miRNAs in microglia upon lipopolysaccharide (LPS)-mediated activation, compared to untreated primary microglia cells was predicted to target Ca2+/calmodulin dependent kinase 2a (CAMK2A). Further, luciferase reporter assay confirmed that miR-142-3p targets the 3′UTR of Camk2a. CAMK2A has been implicated in regulating the expression of brain-derived neurotrophic factor (BDNF) and long-term potentiation (LTP), a cellular mechanism underlying memory and learning. Given this, this study further focused on understanding the miR-142-3p mediated regulation of the CAMK2A-BDNF pathway via Cyclic AMP-responsive element-binding protein (CREB) in activated microglia. The results revealed that CAMK2A was downregulated in activated microglia, suggesting an inverse relationship between miR-142-3p and Camk2a in activated microglia. Overexpression of miR-142-3p in microglia was found to decrease the expression of CAMK2A and subsequently BDNF through regulation of CREB phosphorylation. Functional analysis through shRNA-mediated stable knockdown of CAMK2A in microglia confirmed that the regulation of BDNF by miR-142-3p is via CAMK2A. Overall, this study provides a database of differentially expressed miRNAs in activated primary microglia and reveals that microglial miR-142-3p regulates the CAMK2A-CREB-BDNF pathway which is involved in synaptic plasticity.

18 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
AKAparna Karthikeyan
Aparna Karthikeyan
NGNeelima Gupta
Neelima Gupta
CTCarol Tang
Carol Tang
KMKarthik Mallilankaraman
Karthik Mallilankaraman
MSMaskomani Silambarasan
Maskomani Silambarasan
SDS Thameem Dheen
S Thameem Dheen
Oncotarget | https://doi.org/10.18632/oncotarget.25116 Aparna Karthikeyan, Neelima Gupta, Carol Tang, Karthik Mallilankaraman, Maskomani Silambarasan, Meng Shi, Lei Lu, Beng Ti Ang, Eng-Ang Ling, Thameem S. Dheen Microglial SMAD4 regulated by microRNA-146a promotes migration of microglia which support tumor progression in a glioma environment